Appropriateness of Frozen Plasma Use in Canada
研究概览
地位
条件
详细说明
Objectives: We will (1) systematically review the evidence for the use of Frozen Plasma transfusions, (2) establish appropriateness ratings for all clinical scenarios for which Frozen Plasma is transfused, and (3) perform a 3-month prospective study to understand the current use and the appropriateness of use of Frozen Plasma in 12 Canadian academic centres.
Methods and Analysis: Following a well established methodology to evaluate medical therapies developed at RAND/UCLA, the investigators will purposively employ different epidemiologic techniques to assess the current use and appropriateness of Frozen Plasma transfusions in Canada.
First, we will undertake a thorough systematic review of the evidence for the use of Frozen Plasma across all indications.
The RAND modified Delphi methodology will then be used to determine the appropriateness of transfusing Frozen Plasma across a comprehensive set of clinical scenarios. A panel of 9 experts representing relevant clinical specialties will use the evidence from the systematic review to determine the appropriateness ratings (an ordinal scale of 1-9) for each clinical scenario.
Subsequently, we will undertake a prospective cohort study of all episodes of Frozen Plasma transfusions (approximately 5000 episodes) at 10 Canadian academic centres (17 hospitals) using the appropriateness ratings. Trained research assistants will identify all transfusion episodes via the blood bank and perform a chart review to obtain demographic variables (age, sex, weight), clinical variables (diagnosis, coagulopathy, indications for frozen plasma transfusions, other blood product transfusions), and laboratory (pre and posttransfusion coagulation tests) information. These data will allow mapping of each transfusion event onto a specific clinical scenario rated by the expert panel and the assignment of an appropriateness rating. We will also determine the total number of patients and the number of patients for each of the largest user groups of Frozen Plasma at each hospital. The primary outcomes for the prospective cohort study, the proportion of inappropriate transfusions (appropriateness) and the proportion of patients transfused (overall utilization), will be initially examined using descriptive statistics. Using hierarchical modeling, a logistic regression analysis will be used to examine the proportion of inappropriate transfusions while controlling for indication, hospital, and patient factors. For the analysis of overall utilization of Frozen Plasma, a chi-square analysis will be used to compare the proportion of patients transfused in the largest user groups at the different hospitals. A secondary analysis will examine the dose of Frozen Plasma transfused.
Generated Research: From the systematic reviews, appropriateness ratings, and the results of the cohort study, we will have summarized the evidence supporting the use of Frozen Plasma, produced detailed clinical guidelines outlining the appropriate and inappropriate indications for Frozen Plasma and provided an understanding of the variation in use and appropriateness of Frozen Plasma. Each of these elements can then be used by hospitals in Canada and elsewhere to improve the current use of Frozen Plasma. Understanding of the variation in Frozen Plasma will allow for a framework to improve transfusion practice and identify those areas of Frozen Plasma use that merit the greatest attention for further research.
研究类型
注册 (实际的)
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- All subjects receiving frozen plasma or PCC transfusions
Exclusion Criteria:
No subjects excluded -
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The primary outcome for the appropriateness of Frozen Plasma transfusions will be the proportion of appropriate transfusion episodes.
大体时间:2 months
|
Each transfusion episode will be the unit of analysis as a single patient may receive both inappropriate and appropriate transfusions.
|
2 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The number of units transfused per patient will be the secondary outcome.
大体时间:2 months
|
The investigators consider whether or not a patient received either Frozen Plasma or a prothrombin complex concentrate as the most clinically important outcome.
The investigators will also collect data on the total number of patients in hospital for the study period.
This outcome is also important as differences in transfusion dose will have an important impact on the cost of Frozen Plasma and prothrombin complex concentrate transfusions and will not be captured in an analysis looking solely at the proportion of patients transfused
|
2 months
|
合作者和调查者
调查人员
- 首席研究员:Alan T Tinmouth, MD, MSc、Ottawa Hospital Research Institute
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.